Comparative Pharmacology
Head-to-head clinical analysis: HUMALOG MIX 50 50 PEN versus NOVOLOG.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HUMALOG MIX 50 50 PEN versus NOVOLOG.
HUMALOG MIX 50/50 PEN vs NOVOLOG
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Insulin lispro is a rapid-acting insulin analog that lowers blood glucose by binding to insulin receptors on liver, muscle, and adipose tissue, promoting glucose uptake and storage, and inhibiting hepatic glucose production.
Insulin analog that lowers blood glucose by binding to insulin receptors, enhancing peripheral glucose uptake, and inhibiting hepatic glucose production.
Subcutaneous injection, 0.5 to 1 unit/kg/day divided into two doses (before breakfast and before dinner), individualized based on blood glucose levels.
Subcutaneous injection: 0.5-1 unit/kg/day divided into 3 or more doses given within 15 minutes before or after meals. Typical total daily dose range 0.5-1.5 units/kg.
None Documented
None Documented
Terminal half-life: 0.5-1.0 hour (insulin lispro); clinical context: short duration due to rapid clearance.
Terminal elimination half-life is 1.2-1.5 hours in healthy individuals, reflecting rapid clearance. In renal impairment (e.g., eGFR <30 mL/min), half-life may be prolonged up to 2-3 hours due to reduced degradation.
Renal: 75-80% as metabolites; hepatic: 20-25% via biliary elimination.
Renal excretion accounts for approximately 60-80% of insulin aspart degradation products; unchanged drug is minimally excreted. Biliary/fecal excretion is negligible (<10%).
Category C
Category C
Insulin Analog
Insulin Analog